(Z)-3-({3-[(3-dimethylaminopropyl)-methyl-carbamoyl]-phenylamino}-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester | 466694-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (Z)-3-({3-[(3-dimethylaminopropyl)-methyl-carbamoyl]-phenylamino}-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester
• 英文别名: methyl 3-(Z)-[1-{3-[(3-dimethylamino-propyl)-N-methyl-carbamoyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate；methyl (3Z)-3-[[3-[3-(dimethylamino)propyl-methylcarbamoyl]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate
• CAS: 466694-65-5
• 化学式: C₃₀H₃₂N₄O₄
• 分子量: 512.608
• InChiKey: QMMGKHPGTDFTHI-RQZHXJHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.43
• 重原子数：
  38.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  90.98
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  (E)-methyl 1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate 、 3-airino-N-(3-dimethylamino-propyl)-N-methyl-benzamide 生成 (Z)-3-({3-[(3-dimethylaminopropyl)-methyl-carbamoyl]-phenylamino}-phenyl-methylene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid methyl ester
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Substituted indolinones
  申请人：——

  公开号：US20030092756A1

  公开（公告）日：2003-05-15

  The present invention relates to indolinones substituted in the 6-position of general formula 1 wherein R 1 to R 5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一种通式1中6位取代的吲哚酮，其中R1至R5和X的定义如权利要求1中定义的，其异构体和盐，特别是具有有价值的药理特性的生理上可接受的盐，特别是对各种受体酪氨酸激酶和细胞周期蛋白/CDK复合物以及内皮细胞增殖具有抑制作用的物质，含有这些化合物的药物组合物，其用途和制备这些化合物的方法。
• Medicaments for the Treatment or Prevention of Fibrotic Diseases
  申请人：Park Edward John

  公开号：US20060154939A1

  公开（公告）日：2006-07-13

  The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R 1 to R 5 and X are defined as in claim 1 , the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

  本发明涉及通式为 其中 R 1 至 R 5 和X的定义如权利要求 1 4.3.2 异构体及其盐类，特别是其生理上可接受的盐类，可作为预防或治疗特定纤维化疾病的药物。
• MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1830842B1

  公开（公告）日：2009-04-22
• US6858641B2
  申请人：——

  公开号：US6858641B2

  公开（公告）日：2005-02-22